DelveInsight’s “Hereditary Transthyretin Amyloidosis Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Hereditary Transthyretin Amyloidosis pipeline landscape. It covers the Hereditary Transthyretin Amyloidosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hereditary Transthyretin Amyloidosis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Hereditary Transthyretin Amyloidosis Pipeline? Click here to explore the therapies and trials making headlines @ Hereditary Transthyretin Amyloidosis Pipeline Outlook Report
Key Takeaways from the Hereditary Transthyretin Amyloidosis Pipeline Report
Want to know which companies are leading innovation in Hereditary Transthyretin Amyloidosis? Dive into the full pipeline insights @ Hereditary Transthyretin Amyloidosis Clinical Trials Assessment
The Hereditary Transthyretin Amyloidosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Hereditary Transthyretin Amyloidosis Pipeline Report also highlights the unmet needs with respect to the Hereditary Transthyretin Amyloidosis.
Hereditary Transthyretin Amyloidosis Overview
Hereditary transthyretin (ATTR) amyloidosis is characterized by a slowly progressive peripheral sensorimotor and/or autonomic neuropathy as well as non-neuropathic changes of cardiomyopathy, nephropathy, vitreous opacities, and CNS amyloidosis. It is a rare inherited condition characterized by abnormal build-up of a protein called amyloid in the body’s organs and tissues.
Hereditary Transthyretin Amyloidosis Emerging Drugs Profile
Vutrisiran is an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of ATTR amyloidosis, which encompasses both hereditary (hATTR) and wild-type (wtATTR) amyloidosis. It is designed to target and silence specific messenger RNA, blocking the production of wild-type and variant transthyretin (TTR) protein before it is made. Quarterly administration of vutrisiran may help to reduce deposition and facilitate the clearance of TTR amyloid deposits in tissues and potentially restore function to these tissues. Vutrisiran utilizes Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate delivery platform, designed for increased potency and high metabolic stability that allows for infrequent subcutaneous injections. HELIOS-B is a randomized, double-blind, placebo-controlled Phase 3 study of ~600 adult patients with ATTR amyloidosis with cardiomyopathy (including both hATTR and wtATTR amyloidosis). The U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for vutrisiran, an investigational RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The FDA has set an action date of April 14, 2022 under the Prescription Drug User Fee Act (PDUFA), and the Agency has indicated that they are not currently planning an advisory committee meeting as part of the NDA review.
AKCEA-TTR-LRx is an antisense drug developed using Ionis’ proprietary LIgand Conjugated Antisense (LICA) technology platform and is designed to inhibit production of TTR. It was discovered by Ionis and is being co-developed by Ionis and Akcea. In a Phase 1 clinical trial, patients treated with AKCEA-TTR-LRx experienced reductions in TTR of up to 94 percent at the highest dose. CARDIO-TTRansform is a global, double-blind, randomized, placebo-controlled Phase III cardiovascular outcome study. It is designed to compare AKCEA-TTR-LRx to placebo in patients with both wild type and hereditary ATTR cardiomyopathy who are on the current available standard of care.
If you’re tracking ongoing Hereditary Transthyretin Amyloidosis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Hereditary Transthyretin Amyloidosis Treatment Drugs
The Hereditary Transthyretin Amyloidosis Pipeline report provides insights into:-
Hereditary Transthyretin Amyloidosis Companies
Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Eidos Therapeutics, Intellia Therapeutics, Corino Therapeutics, Novo Nordisk and others.
Hereditary Transthyretin Amyloidosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
Hereditary Transthyretin Amyloidosis Products have been categorized under various Molecule types such as,
From emerging drug candidates to competitive intelligence, the Hereditary Transthyretin Amyloidosis Pipeline Report covers it all – check it out now @ Hereditary Transthyretin Amyloidosis Market Drivers and Barriers, and Future Perspectives
Scope of the Hereditary Transthyretin Amyloidosis Pipeline Report
Stay ahead in Healthcare Research – discover what’s next for the Hereditary Transthyretin Amyloidosis Treatment landscape in this detailed analysis @ Hereditary Transthyretin Amyloidosis Emerging Drugs and Major Players
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight
